Stock Scorecard



Stock Summary for Adial Pharmaceuticals Inc (ADIL) - $1.02 as of 11/20/2024 4:32:22 PM EST

Total Score

12 out of 30

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ADIL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ADIL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ADIL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ADIL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ADIL (30 out of 90)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 0

Latest News for for ADIL

EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder - Adial Pharmaceuticals ( NASDAQ:ADIL ) 11/14/2024 1:00:00 PM
This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Turning Point Brands ( NYSE:TPB ) 11/14/2024 12:53:00 PM
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer 11/5/2024 1:30:00 PM
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - Adial Pharmaceuticals ( NASDAQ:ADIL ) , Virpax Pharmaceuticals ( NASDAQ:VRPX ) 11/5/2024 1:30:00 PM
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference 10/23/2024 1:00:00 PM
Analyst Predicts Bitcoin High In Weeks, $90K By Year-End; TSMC Nears $1 Trillion Valuation After 8% Premarket Surge - Top Headlines Today While US Slept 10/17/2024 2:09:00 PM
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate - Adial Pharmaceuticals ( NASDAQ:ADIL ) 10/17/2024 12:30:00 PM
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update 8/14/2024 12:30:00 PM
EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder - Adial Pharmaceuticals ( NASDAQ:ADIL ) 8/13/2024 12:30:00 PM
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder 8/7/2024 1:00:00 PM

Financial Details for ADIL

Company Overview

Ticker ADIL
Company Name Adial Pharmaceuticals Inc
Country USA
Description Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 1.02
Price 4 Years Ago 42.50
Last Day Price Updated 11/20/2024 4:32:22 PM EST
Last Day Volume 96,588
Average Daily Volume 197,019
52-Week High 4.17
52-Week Low 0.77
Last Price to 52 Week Low 32.47%

Valuation Measures

Trailing PE N/A
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -25.18
Free Cash Flow Ratio 1.26
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 6.78
Total Cash Per Share 0.81
Book Value Per Share Most Recent Quarter 2.46
Price to Book Ratio 1.10
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 6,405,800
Market Capitalization 6,533,916
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 59.76%
Reported EPS 12 Trailing Months -2.94
Reported EPS Past Year -1.59
Reported EPS Prior Year -1.68
Net Income Twelve Trailing Months -13,046,994
Net Income Past Year -5,123,341
Net Income Prior Year -12,731,416
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00

Balance Sheet

Total Cash Most Recent Quarter 5,204,346
Total Cash Past Year 2,827,082
Total Cash Prior Year 4,001,794
Net Cash Position Most Recent Quarter 5,175,258
Net Cash Position Past Year 2,797,994
Long Term Debt Past Year 29,088
Long Term Debt Prior Year 29,088
Total Debt Most Recent Quarter 29,088
Equity to Debt Ratio Past Year 0.99
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 4,083,529
Total Stockholder Equity Prior Year 3,276,494
Total Stockholder Equity Most Recent Quarter 5,883,673

Free Cash Flow

Free Cash Flow Twelve Trailing Months -6,691,040
Free Cash Flow Per Share Twelve Trailing Months -1.04
Free Cash Flow Past Year -13,613,618
Free Cash Flow Prior Year 0

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.01
20-Day Bollinger Lower Band 0.93
20-Day Bollinger Middle Band 1.03
20-Day Bollinger Upper Band 1.12
Beta 1.30
RSI 47.19
50-Day SMA 12.31
150-Day SMA 0.00
200-Day SMA 27.32

System

Modified 11/20/2024 4:32:23 PM EST